Eptifibatide

Drug Profile

Eptifibatide

Alternative Names: Integrelin; Integrilin; Intrifiban; SCH 60936

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer GlaxoSmithKline; Merck & Co; Millennium Pharmaceuticals; Schering-Plough
  • Class Ischaemic heart disorder therapies; Peptides
  • Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Myocardial infarction; Unstable angina pectoris
  • Discontinued Stroke

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Mar 2009 Discontinued - Phase-III for Acute coronary syndromes in World (IV)
  • 15 Oct 2008 Safety and efficacy data from the three-year ASSIST trial in Myocardial infarction released by the University of Ottawa Heart Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top